Mouse Anti-ETV6 Antibody (1A7) (CBMAB-0362-YC)

Mouse

Human

1A7

IgG2b

ChIP, IP, WB, MA

Recombinant protein

Human

IgG2b

Monoclonal

The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Supernatant

Store at 4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

ETV6

ETV6 (ETS variant 6) is an ETS family transcription factor. ETV6 contains two functional domains: a N-terminal pointed (PNT) domain that is involved in protein-protein interactions with itself and other proteins, and a C-terminal DNA-binding domain. It is proved that ETV6 is required for hematopoiesis and maintenance of the developing vascular network. Also, ETV6 is known to be involved in a large number of chromosomal rearrangements associated with leukemia and congenital fibrosarcoma.

ETS Variant 6; Ets Variant Gene 6 (TEL Oncogene); ETS Translocation Variant 6; ETS-Related Protein Tel1; TEL; TEL1 Oncogene; Ets Variant 6; TEL Oncogene; TEL/ABL; TEL1; THC5

Transcriptional repressor; binds to the DNA sequence 5'-CCGGAAGT-3'. Plays a role in hematopoiesis and malignant transformation.

Cell differentiation Source: GO_Central
Hematopoietic stem cell proliferation Source: UniProtKB
Mesenchymal cell apoptotic process Source: Ensembl
Negative regulation of transcription by RNA polymerase II Source: NTNU_SB
Neurogenesis Source: Ensembl
Regulation of transcription by RNA polymerase II Source: GO_Central
Vitellogenesis Source: Ensembl

Nucleus

A chromosomal aberration involving ETV6 is found in a form of chronic myelomonocytic leukemia (CMML). Translocation t(5;12)(q33;p13) with PDGFRB. It is characterized by abnormal clonal myeloid proliferation and by progression to acute myelogenous leukemia (AML).
Chromosomal aberrations involving ETV6 are found in acute myeloid leukemia (AML). Translocation t(12;22)(p13;q11) with MN1 (PubMed:7731705). Translocation t(4;12)(q12;p13) with CHIC2 (PubMed:10477709).
Chromosomal aberrations involving ETV6 are found in childhood acute lymphoblastic leukemia (ALL). Translocations t(12;21)(p12;q22) and t(12;21)(p13;q22) with RUNX1/AML1.
A chromosomal aberration involving ETV6 is found in a form of pre-B acute lymphoid leukemia. Translocation t(9;12)(p24;p13) with JAK2.
A chromosomal aberration involving ETV6 and JAK2 is found in an atypical chronic myelogenous leukemia. Translocation t(9;15;12)(p24;q15;p13).
A chromosomal aberration involving ETV6 is found in myelodysplastic syndrome (MDS) with basophilia. Translocation t(5;12)(q31;p13) with ACSL6.
A chromosomal aberration involving ETV6 is found in acute eosinophilic leukemia (AEL). Translocation t(5;12)(q31;p13) with ACSL6.
A chromosomal aberration involving ETV6 is found in myelodysplastic syndrome (MDS). Translocation t(1;12)(p36.1;p13) with MDS2.
A chromosomal aberration involving ETV6 is found in acute lymphoblastic leukemia. Translocation t(9;12)(p13;p13) with PAX5.
Myeloproliferative disorder chronic with eosinophilia (MPE):
The gene represented in this entry is involved in disease pathogenesis. A chromosomal aberration involving ETV6 is found in many instances of myeloproliferative disorder chronic with eosinophilia. Translocation t(5;12) with PDGFRB on chromosome 5 creating an ETV6-PDGFRB fusion protein. A hematologic disorder characterized by malignant eosinophils proliferation.
Leukemia, acute myelogenous (AML):
A subtype of acute leukemia, a cancer of the white blood cells. AML is a malignant disease of bone marrow characterized by maturational arrest of hematopoietic precursors at an early stage of development. Clonal expansion of myeloid blasts occurs in bone marrow, blood, and other tissue. Myelogenous leukemias develop from changes in cells that normally produce neutrophils, basophils, eosinophils and monocytes.
Thrombocytopenia 5 (THC5):
A form of thrombocytopenia, a hematologic disorder defined by a decrease in the number of platelets in circulating blood, resulting in the potential for increased bleeding and decreased ability for clotting. THC5 is an autosomal dominant disorder, associated with an increased susceptibility to the development of hematologic and solid malignancies.

Phosphorylation of Ser-257 by MAPK14 (p38) inhibits ETV6 transcriptional repression.